Pixelgen Technologies Awarded $14.7 Million in Blended Funding from European Innovation Council Accelerator

Funding to accelerate platform expansion into new applications in cell-to-cell interactions and tissue

STOCKHOLM, June 30, 2025 /PRNewswire/ -- Pixelgen Technologies today announced that it has been awarded grant and equity financing of EUR 12.5 M ($14.7 million) from the European Innovation Council (EIC) Accelerator, a funding initiative under the European Union's Horizon Europe program designed to support highly innovative start-ups with disruptive technologies. Pixelgen will use the financing to expand the applications of its Pixelgen Proxiome Kit, launched earlier this year as the first kit and software for protein interactome analysis of single cells at high capacity.

"We're thrilled to receive this highly competitive funding from the EIC," said Pixelgen co-founder and CEO Simon Fredriksson. "The process was rigorous, and the award further reinforces the value of Pixelgen's technology to increase our understanding of complex cellular and functional cell surface arrangements, which we believe will advance drug development and deepen our understanding of precision medicine. The response from leading researchers in industry and academia to our Proxiome Kit has been very enthusiastic, and this grant will help accelerate its expansion into new applications, including cell-to-cell interactions, communication, and FFPE tissues."

The EIC selected 40 innovative start-ups and small-to-medium-sized enterprises out of 150 applicants in its latest evaluation round to receive funding. The companies were chosen for their "transformative technologies and strong commercial promise," according to the EIC.  

The Pixelgen Proxiome Kit is the first in a new product line by Pixelgen offering researchers the highest resolution of single cell analyses by providing a new omics dimension (protein interactomics), for novel insights into disease mechanisms, drug response, biomarker discovery, and more, in cancer, hematology, immunology, and cell therapy research. It's based on the company's proprietary Proximity Network Assay, which delivers nanoscale spatial analysis of immune cell proteins at scale and was recently presented on BioRxiv.

Pixelgen is backed by leading investors, including Industrifonden, Sweden's venture capital fund, and Navigare Ventures.

About Pixelgen Technologies
Pixelgen Technologies AB is on a mission to deliver biology at the highest resolution by understanding the molecular basis of cellular function with new tools and technologies that decipher the protein interactomics of single cells in unprecedented ways. The company's patented Proximity Network Assay delivers nanoscale spatial analysis of immune cell proteins at ultra-high capacity and underpins the Pixelgen Proxiome Kit for precision medicine. A foundational technology, the Proximity Network Assay will power a portfolio of products for translational research to accelerate advances in immunology, hematology, and cell therapy. Pixelgen was founded in 2020 by a team of passionate, experienced innovators and entrepreneurs and is venture-backed.

Contacts

Corporate:
Annika Branting
[email protected]
+46 762-69 68 46

Media:
Susan Thomas
[email protected]
+1 (619) 540-9195

SOURCE Pixelgen Technologies